Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib + Trastuzumab + Pertuzumab in PIK3CA-mutant, HER2-positive Advanced Breast Cancer
NCT04253561Phase 1Completed
- Sponsor
- SOLTI
- Start
- Feb 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipatasertib in breast cancer, sponsored by SOLTI. Primary endpoint: Recommended Phase 2 Dose at 28 days. Started Feb 2020; status: completed.
02
Drugs
ipatasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04253561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04253561.